Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research

Rates of hemorrhage during warfarin therapy for atrial fibrillation

Tara Gomes, Muhammad M. Mamdani, Anne M. Holbrook, J. Michael Paterson, Chelsea Hellings and David N. Juurlink
CMAJ February 05, 2013 185 (2) E121-E127; DOI: https://doi.org/10.1503/cmaj.121218
Tara Gomes
The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tara.gomes@ices.on.ca
Muhammad M. Mamdani
The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne M. Holbrook
The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Michael Paterson
The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chelsea Hellings
The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David N. Juurlink
The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Article Information

vol. 185 no. 2 E121-E127
DOI 
https://doi.org/10.1503/cmaj.121218
PubMed 
23184840
History 
  • Published online February 4, 2013.

Article Versions

  • Latest version (November 26, 2012 - 08:19).
  • Latest version (January 21, 2013 - 08:32).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2013 Canadian Medical Association or its licensors

Author Information

  1. Tara Gomes, MHSc⇑,
  2. Muhammad M. Mamdani, PharmD MPH,
  3. Anne M. Holbrook, MD PharmD,
  4. J. Michael Paterson, MSc,
  5. Chelsea Hellings, MSc,
  6. David N. Juurlink, MD PhD
  1. The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
  1. Correspondence to:
    Tara Gomes, tara.gomes{at}ices.on.ca
View Full Text

Usage statistics: November 2012 to May 2022

AbstractFullPdf
Nov 2012244271577
Dec 20128932947
Jan 20138562492
Feb 20131778185397
Mar 201364771235
Apr 201340872155
May 201336962169
Jun 201326847118
Jul 201312256266
Aug 201318578260
Sep 201318946114
Oct 2013208118155
Nov 20131616196
Dec 20131363494
Jan 20141444984
Feb 20141413984
Mar 20141675198
Apr 20141553780
May 20141424071
Jun 20141185785
Jul 20141417895
Aug 20141033129
Sep 20142217885
Oct 20141666085
Nov 20142145450
Dec 20141024242
Jan 20151243643
Feb 20151102659
Mar 20151776373
Apr 20151123372
May 20151532656
Jun 20151013153
Jul 2015793448
Aug 20151003245
Sep 20156731138
Oct 201513024663
Nov 201512124645
Dec 201511821736
Jan 201613121875
Feb 201610018467
Mar 20169323975
Apr 20168324138
May 201610630377
Jun 201610227651
Jul 20168725935
Aug 201611535331
Sep 20169028825
Oct 201610426338
Nov 201614125832
Dec 20167434925
Jan 20176915023
Feb 2017584824
Mar 2017593630
Apr 2017634923
May 2017553424
Jun 2017392736
Jul 2017462714
Aug 2017622917
Sep 2017483424
Oct 2017512115
Nov 2017644730
Dec 20175516238
Jan 20184520720
Feb 2018439045
Mar 2018469342
Apr 2018509837
May 2018499734
Jun 2018387951
Jul 2018355916
Aug 2018356216
Sep 2018176520
Oct 2018247522
Nov 2018128222
Dec 201838721
Jan 201968123
Feb 2019106619
Mar 2019176525
Apr 201995422
May 2019182814
Jun 20194729
Jul 201993128
Aug 201944122
Sep 201944724
Oct 2019114323
Nov 2019173922
Dec 201993938
Jan 2020164831
Feb 2020134229
Mar 202092825
Apr 202068019
May 2020108713
Jun 202095224
Jul 202063119
Aug 202054110
Sep 202013539
Oct 2020206221
Nov 2020126412
Dec 2020148412
Jan 2021126315
Feb 2021125413
Mar 2021166818
Apr 2021198718
May 2021127528
Jun 20211112221
Jul 2021144720
Aug 202193220
Sep 202196324
Oct 2021114836
Nov 2021133228
Dec 2021117429
Jan 202295519
Feb 202295811
Mar 2022137011
Apr 2022218728
May 202253114

Cited By...

  • 140 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 185 (2)
CMAJ
Vol. 185, Issue 2
5 Feb 2013
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rates of hemorrhage during warfarin therapy for atrial fibrillation
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rates of hemorrhage during warfarin therapy for atrial fibrillation
Tara Gomes, Muhammad M. Mamdani, Anne M. Holbrook, J. Michael Paterson, Chelsea Hellings, David N. Juurlink
CMAJ Feb 2013, 185 (2) E121-E127; DOI: 10.1503/cmaj.121218

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Rates of hemorrhage during warfarin therapy for atrial fibrillation
Tara Gomes, Muhammad M. Mamdani, Anne M. Holbrook, J. Michael Paterson, Chelsea Hellings, David N. Juurlink
CMAJ Feb 2013, 185 (2) E121-E127; DOI: 10.1503/cmaj.121218
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Acknowledgement
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • PubMed
  • Google Scholar

Cited By...

  • Adverse event rates associated with oral anticoagulant treatment early versus later after hospital discharge in older adults: a retrospective population-based cohort study
  • Cardioembolic stroke: everything has changed
  • Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF
  • Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
  • Association of Atrial Fibrillation and Oral Anticoagulant Use With Perioperative Outcomes After Major Noncardiac Surgery
  • Clinical Application of Prothrombin Complex Concentrate in Blood Management in Patients
  • Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective--2016 Update
  • Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke
  • Plasma versus prothrombin complex concentrate for warfarin-associated major bleeding: a systematic review
  • Adherence to oral anticoagulants in patients with atrial fibrillation--a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol
  • Rates of Ischemic Stroke During Warfarin Treatment for Atrial Fibrillation
  • The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study
  • Evaluation of an initiation protocol of 4 mg of warfarin for atrial fibrillation in the outpatient setting
  • Use of blood products in patients with anticoagulant-related major bleeding: An analysis of inhospital outcomes
  • Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention: A Contemporary Review
  • Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
  • Warfarin and absolute risk of hemorrhagic stroke
  • Google Scholar

More in this TOC Section

  • The risk of death or unplanned readmission after discharge from a COVID-19 hospitalization in Alberta and Ontario
  • The link between medical conditions and fatal drownings in Canada: a 10-year cross-sectional analysis
  • Projected estimates of cancer in Canada in 2022
Show more Research

Similar Articles

Collections

  • Topics
    • Cardiology: arrhythmias
    • Drugs: adverse reactions

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire